NovoCure Limited - Depositary Receipt (Common Stock) - Laporan Laba Rugi (TTM)

NovoCure Limited - Depositary Receipt (Common Stock)
BR ˙ BOVESPA
R$ 9.00 0.00 (0.00%)
2025-07-21
BAHAGING PRESYO
Laporan Laba Rugi (TTM)

Laporan Laba Rugi NovoCure Limited - Depositary Receipt (Common Stock) menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 450 494 527 545 546 535 538 545 543 538 522 508 504 509 526 550 578 605 622 630
Change (%) 9.95 6.65 3.34 0.17 -1.97 0.53 1.37 -0.48 -0.88 -2.86 -2.84 -0.72 1.06 3.20 4.62 5.05 4.76 2.72 1.36
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 103 106 108 111 113 114 116 115 115 114 116 122 124 128 132 132 136 136 141 148
Change (%) 3.18 1.78 2.89 1.63 1.17 1.17 -0.08 -0.40 -0.67 1.65 4.75 1.93 2.85 3.20 0.48 2.48 0.48 3.55 4.84
% of Revenue 22.87 21.46 20.48 20.39 20.69 21.35 21.49 21.18 21.20 21.24 22.23 23.96 24.60 25.04 25.04 24.05 23.46 22.50 22.68 23.46
Gross Operating Profit 347 388 419 434 433 421 422 430 428 424 406 386 380 382 394 418 442 469 481 482
Change (%) 11.95 7.98 3.45 -0.20 -2.79 0.36 1.76 -0.50 -0.94 -4.07 -5.00 -1.56 0.48 3.21 6.01 5.86 6.07 2.49 0.34
% of Revenue 77.13 78.54 79.52 79.61 79.31 78.65 78.51 78.82 78.80 78.76 77.77 76.04 75.40 74.96 74.96 75.95 76.54 77.50 77.32 76.54
SG&A 216 225 232 246 253 263 269 279 289 306 331 354 380 387 389 384 384 427 433 440
Change (%) 4.24 3.12 5.61 3.01 4.06 2.25 3.54 3.62 6.13 8.07 6.90 7.33 1.85 0.42 -1.27 0.02 11.33 1.36 1.55
% of Revenue 48.10 45.60 44.10 45.07 46.34 49.19 50.03 51.10 53.21 56.97 63.38 69.73 75.39 75.97 73.92 69.76 66.42 70.59 69.65 69.78
R&D 112 132 153 173 188 201 198 204 208 206 224 222 224 221 213 212 211 209 212 212
Change (%) 18.13 15.64 13.36 8.85 6.86 -1.83 3.42 1.87 -1.01 8.48 -0.74 0.75 -1.15 -3.67 -0.22 -0.82 -0.62 1.04 0.42
% of Revenue 24.85 26.70 28.95 31.76 34.52 37.62 36.74 37.49 38.37 38.32 42.79 43.71 44.36 43.39 40.50 38.62 36.47 34.59 34.03 33.71
OpEx 431 464 493 530 554 579 582 598 612 627 671 698 728 735 733 728 730 773 786 800
Change (%) 7.59 6.38 7.41 4.63 4.42 0.62 2.78 2.25 2.42 7.03 3.98 4.29 1.10 -0.33 -0.65 0.22 5.87 1.66 1.83
% of Revenue 95.82 93.77 93.53 97.22 101.55 108.17 108.26 109.77 112.77 116.53 128.39 137.40 144.35 144.40 139.46 132.43 126.34 127.68 126.36 126.95
Operating Income 19 31 34 15 -8 -44 -44 -53 -69 -89 -148 -190 -224 -226 -207 -178 -152 -168 -164 -170
Change (%) 63.98 10.69 -55.61 -155.71 418.07 1.64 19.89 30.16 28.29 66.86 28.00 17.71 1.18 -8.28 -14.02 -14.66 10.08 -2.18 3.63
% of Revenue 4.18 6.23 6.47 2.78 -1.55 -8.17 -8.26 -9.77 -12.77 -16.53 -28.39 -37.40 -44.35 -44.40 -39.46 -32.43 -26.34 -27.68 -26.36 -26.95
Interest Expense -17 -18 -18 -16 -11 -3 -3 -4 -3 -3 -2 -1 -3 -3 -3 -5 -9 -10 -10 -14
Change (%) 5.02 1.22 -9.42 -29.79 -69.60 -27.24 51.46 -9.89 -2.40 -51.26 -36.12 195.57 8.18 -0.00 63.33 57.85 20.87 -0.00 33.86
% of Revenue -3.72 -3.56 -3.38 -2.96 -2.07 -0.64 -0.47 -0.70 -0.63 -0.62 -0.31 -0.20 -0.61 -0.65 -0.63 -0.99 -1.48 -1.71 -1.66 -2.20
Net Income 19 20 12 -5 -27 -58 -59 -68 -82 -93 -141 -174 -197 -207 -193 -169 -150 -169 -164 -171
Change (%) 3.43 -40.79 -138.95 490.54 116.31 0.89 15.91 19.71 13.28 52.32 23.70 13.14 4.96 -6.91 -12.47 -11.21 12.58 -2.63 4.12
% of Revenue 4.26 4.01 2.22 -0.84 -4.94 -10.91 -10.94 -12.52 -15.05 -17.20 -26.98 -34.35 -39.14 -40.65 -36.67 -30.67 -25.93 -27.86 -26.41 -27.13

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista